Biotts publishes peer-reviewed research in Pharmaceutics (MDPI) validating MTC-Y™ technology for transdermal delivery of lidocaine and tetracaine.

Biotts has been granted US Patent No. 12,478,679 B2 for its MTC-Y transdermal carrier technology. The patent was issued by the USPTO on 25 November 2025.

Biotts represented Polish transdermal innovation at BioJapan 2025 in Yokohama, Japan – Asia’s premier bio-industry partnering event. Read about our experience.

At Biotts, we offer tailored, GMP-compliant research and development services specifically designed to meet the rigorous needs of pharmaceutical, biotechnology, cosmetics, and dietary supplements companies. Our multidisciplinary team, supported by advanced GMP-certified laboratories, ensures comprehensive project support from initial formulation through to analytical validation.

Biotts is pleased to announce the issuance of US Patent No. 12,201,621 B2 on January 21, 2025. This patent covers a novel topical anesthetic formulation, MTC-A4, which combines tetracaine and lidocaine in a unique delivery system designed to provide an improved treatment option compared to existing therapies like Pliaglis.

Biotts is excited to be a part of Biotech Showcase 2025, taking place January 13-15 in San Francisco! This leading industry event brings together key players in the biotech world – from investors to innovators – to explore the latest advancements and forge new partnerships.